Management of relapsed/refractory mantle cell lymphoma: A review of current therapeutic strategies

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 988-998

  Zaja, Francesco ^a   Federico, Massimo ^b   Vitolo, Umberto ^c   Zinzani, Pier Luigi ^d  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Mantle cell lymphoma; Second line treatment; Targeted therapies

Indexed keywords

ABEXINOSTAT; ALPHA INTERFERON; AURORA A KINASE; BENDAMUSTINE; BIOLOGICAL PRODUCT; BORTEZOMIB; BRUTON TYROSINE KINASE INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; MITOXANTRONE; NAVITOCLAX; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 84899751097     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.825903     Document Type: Review

References (82)

1. McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and management of mantle cell lymphoma. Br J Haematol 2012; 159: 405-426.
2. Swerdlow SH, Campo E, Seto M, et al. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 229-232.
3. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
4. Luminari S, Cesaretti M, Rashid I, et al. Incidence, clinical characteristics and survival of malignant lymphomas: A populationbased study from a cancer registry in northern Italy. Hematol Oncol 2007; 25: 189-197.
5. Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135-141.
6. Kirschey S, Wagner S, Hess G. R elapsed and/or refractory mantle cell lymphoma: What role for temsirolimus? Clin Med Insights Oncol 2012; 6: 153-164.
7. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008; 111: 5683-5690.
8. Camara-Clayette V, Hermine O, Ribrag V. Emerging agents for the treatment of mantle cell lymphoma. Expert Rev Anticancer Ther 2012; 12: 1205-1215.
9. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006; 24: 22-27.
10. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518.
11. Katzenberger T, Petzoldt C, Holler S, et a l. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407.
12. Gill S, Herbert KE, Prince HM, et al. Mantle cell lymphoma with central nervous system involvement: Frequency and clinical features. Br J Haematol 2009; 147: 83-88.
13. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 1997; 89: 2067-2078.
14. Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89: 1421-1429.
15. Hoster E, Dreyling M, Klapper, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
16. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle cell lymphoma. J Clin Oncol 2009; 27: 1209-1213.
17. Orchard J, Garand R, Davis Z, et a l. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non nodal disease. Blood 2003; 101: 4975-4981.
18. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL younger trial of the European mantle cell lymphoma network (MCL net). Blood 2010; 116(Suppl. 1): Abstract 110.
19. Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma:fi nal analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). Blood 2012; 120(Suppl. 1): Abstract 151.
20. Le Gouill S, Callanan M, Macintyre E, et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, aLysa study. Blood 2012; 120(Suppl. 1): Abstract 152.
21. Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-1449.
22. Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-fi eld radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006; 65: 1185-1191.
23. Dreyling M, Hoster E, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): Minutes of the 9th European MCL Network conference. Leuk Lymphoma 2010; 51: 1612-1622.
24. Kluin-Nelemans JC, Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-Alfa: Outcome of the fi rst randomized trial for elderly patients with mantle cell lymphoma. Blood 2011; 118(Suppl. 1): Abstract 439.
25. Dietrich S, Tielesch B, Rieger M, et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 2011; 117: 1901-1910.
26. Forstpointner R, Dreyling M, Repp R, et a l. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
27. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-4479.
28. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
29. Weide R, Hess G, Köp pler H, et a l.; G erman Low grade Lymphoma Study Group. High anti-lymphoma activity of bendamustine/ mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299-1306.
30. Rummel M J, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as fi rst-line treatment for patients with indolent and mantle-cell lymphomas: An openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
31. Visco C, Castegnaro S, Chieregato K, et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol 2012; 48: 68-75.
32. Morschhauser F, Depil S, Jourdan E, et al. Phase II study of gemcitabinedexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370-375.
33. Rodr í guez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007; 48: 2172-2178.
34. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
35. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
36. Ghielmini M, Schmitz SF, Cogliatti S, et al. Swiss Group for Clinical Cancer Research. effect of single-Agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705-711.
37. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003-4008.
38. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
39. Cartron G, Thieblemont C, Solal-Celigny P, et al. Promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-Treated NHL patients-fi rst results from a Phase II study in patients with relapsed/ refractory DLBCL and MCL. Blood 2010; 116(Suppl. 1): Abstract 2878.
40. Reddy N, Greer JP, Goodman S, et al. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Exp Hematol 2012; 40: 359-366.
41. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
42. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reducedintensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
43. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535-3542.
44. Robinson SP, Goldstone AH, Mackinnon S, et al. Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
45. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
46. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
47. O ' Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
48. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105-2112.
49. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116-121.
50. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
51. Zinzani P L, Pellegrini C, Merla E, et al. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study. Hematol Oncol. 2013; 31: 179-182.
52. Kouroukis C T, Fernandez L A, Crump M, et a l. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 2011; 52: 394-399.
53. Baiocchi R A, Alinari L, Lustberg M E, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011; 117: 2442-2451.
54. Chiappella A, Pregno P, Zinzani PL, et al. Weekly infusion of bortezomib in combination with rituximab in relapsed/refractory indolent non-follicular and mantle cell lymphoma is safe and effective: Two-years analysis of phase II trial BRIL06 of Intergruppo Italiano Linfomi (IIL). Blood 2010; 116(Suppl. 1): Abstract 3965.
55. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy refractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014.
56. Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341;NSC 681239) and alvocidib (flavopiridol;NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011; 17: 3388-3397.
57. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28: 418-423.
58. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of singleagent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
59. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, singleagent temsirolimus for relapsed mantle cell lymphoma: A Phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508-514.
60. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
61. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 2011; 12: 361-368.
62. O ' Connor OA, Popplewell L, Winter JN, et al. PILLAR-1: Preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. Blood 2010; 116(Suppl. 1): Abstract 3963.
63. Renner C, Zinzani PL, Gressin R, et al. A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085-1091.
64. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341-347.
65. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
66. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-Agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
67. Eve HE, Carey S, Richardson SJ, et al. Single-Agent lenalidomide in relapsed/refractory mantle cell lymphoma: Results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154-163.
68. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma: Clinical results and modifications of angiogenic biomarkers. Blood 2010; 116(Suppl. 1): Abstract 996.
69. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-Angiogenic biomarkers. Haematologica 2012; 97: 416-422.
70. Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as fi rst-line therapy for patients-65 years with mantle cell lymphoma: Results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011; 118(Suppl. 1): Abstract 2700.
71. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
72. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
73. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
74. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 ä , in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010; 116(Suppl. 1): Abstract 1777.
75. Meadows SA, Kashishian A, Johnson D, et al. CAL-101 (GS-1101), aspecific inhibitor of phosphatidylinositol-3-kinase-delta (PI3K ä), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL). Blood 2011; 118(Suppl.): Abstract 3730.
76. Schatz J H. T argeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: Results, biology, and development strategies. Curr Oncol Rep 2011; 13: 398-406.
77. Evens AM, Spies WG, Helenowski IB, et al. The novel expanded porphyrin, motexafi n gadolinium, combined with [90Y] ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: Preclinical fi ndings and results of a phase I trial. Clin Cancer Res 2009; 15: 6462-6471.
78. Evens AM, Vose JM, Harb WA, et al. A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood 2012; 120:(Suppl. 1): Abstract 55.
79. Palanca-Wessels MC, Flinn IW, Sehn LH, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2012; 120(Suppl. 1): Abstract 56.
80. Davids MS, Roberts AW, Anderson MA, et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-Tolerated in patients with relapsed non-Hodgkin lymphoma: Interim results of a phase I study. Blood 2012; 120(Suppl. 1): Abstract 304.
81. Zhang M, Huck J, Hyer M, et al. effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. J Clin Oncol 2009; 27(Suppl. 1): Abstract 8553.
82. Friedberg J, Mahadevan D, Jung J, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of Aurora A kinase (AAK), in patients (pts) with aggressive B-And T-cell non-Hodgkin lymphoma (NHL). Blood 2012; 120:(Suppl. 1): Abstract 95.